PCDHGB3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-17528
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was developed against Recombinant Protein corresponding to amino acids: SLRLRCSSRPATEGYFQPGVCFKTVPGVLPTYSERTLPYSYNPCAASHSSNTEFKFLNIKAENAAPQDLLCDEASWFESNDNPEMPSNSGNLQ
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for PCDHGB3 Antibody
Immunocytochemistry/ Immunofluorescence: PCDHGB3 Antibody [NBP3-17528]
Immunocytochemistry/Immunofluorescence: PCDHGB3 Antibody [NBP3-17528] - Staining of human cell line BJ shows localization to nucleoplasm, plasma membrane & vesicles.Applications for PCDHGB3 Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
0.25-2 ug/ml
Application Notes
Immunocytochemistry/Immunofluorescence, PFA/Triton X-100 is recommended for fixation/permeabilization.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, pH 7.2, 40% glycerol
Preservative
0.02% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: PCDHGB3
Alternate Names
PCDH-GAMMA-B3, protocadherin gamma subfamily B, 3, protocadherin gamma-B3
Gene Symbol
PCDHGB3
Additional PCDHGB3 Products
Product Documents for PCDHGB3 Antibody
Product Specific Notices for PCDHGB3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...